ERBB2 and breast cancer: Adding pertuzumab to trastuzumab plus chemotherapy achieves pronounced efficacy in early or locally advanced breast cancer patients with HER2 positive, especially in patients with HER2 positive and ER/PR-negative status [3, 10].